-
公开(公告)号：US20240350600A1
公开(公告)日：2024-10-24
申请号：US18754670
申请日：2024-06-26
Applicant: ARAVAX PTY LTD
Inventor： ROBYN O'HEHIR , JENNIFER ROLLAND , SARA PRICKETT
CPC classification number: A61K39/001 , A61K38/00 , A61K38/04 , A61K38/10 , A61K39/35 , G01N33/5005 , A61K2039/57
Abstract: The present invention relates generally to molecules such as peptides, polypeptides and proteins which interact immunologically with T lymphocytes in subjects having peanut allergy, or allergy to other tree nuts, and genetic sequences encoding same. These molecules are preferably immunointeractive with T cells in subjects having an allergy to the Ara H 1 allergen. The molecules of the present invention are useful in the development of diagnostic, therapeutic and prophylactic agents for conditions characterised by an aberrant, inappropriate or otherwise unwanted immune response to Ara h 1 or derivative or homologue thereof.
-
公开(公告)号：US20240350599A1
公开(公告)日：2024-10-24
申请号：US18616880
申请日：2024-03-26
Applicant: ARAVAX PTY LTD
Inventor： ROBYN O'HEHIR , JENNIFER ROLLAND , SARA PRICKETT
CPC classification number: A61K39/001 , A61K38/00 , A61K38/04 , A61K38/10 , A61K39/35 , G01N33/5005 , A61K2039/57
Abstract: The present invention relates generally to molecules such as peptides, polypeptides and proteins which interact immunologically with T lymphocytes in subjects having peanut allergy, or allergy to other tree nuts, and genetic sequences encoding same. These molecules are preferably immunointeractive with T cells in subjects having an allergy to the Ara H 1 allergen. The molecules of the present invention are useful in the development of diagnostic, therapeutic and prophylactic agents for conditions characterised by an aberrant, inappropriate or otherwise unwanted immune response to Ara h 1 or derivative or homologue thereof.
-
公开(公告)号：US12076380B2
公开(公告)日：2024-09-03
申请号：US17492112
申请日：2021-10-01
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Toni Weinschenk , Andrea Mahr , Jens Fritsche , Phillip Mueller , Anita Wiebe , Sarah Kutscher
IPC: A61K39/00 , A61K35/17 , A61K38/04 , C07K7/00 , C07K7/06 , C07K14/435 , C07K14/725 , C07K14/74 , C07K16/18 , C12N5/0783 , C12N15/115 , A61K35/12 , A61K51/10 , C07K7/08 , G01N33/68
CPC classification number: A61K39/0011 , A61K35/17 , A61K38/04 , C07K7/00 , C07K7/06 , C07K14/435 , C07K14/7051 , C07K14/70539 , C07K16/18 , C12N5/0636 , C12N15/115 , A61K2035/124 , A61K39/00111 , A61K2039/5154 , A61K2039/5158 , A61K51/1057 , C07K7/08 , C07K2317/70 , C07K2319/40 , C12N2310/16 , C12N2501/998 , G01N33/6803
Abstract: A peptide consists of the amino acid sequence ALVEQGFTV (SEQ ID NO: 5) in the form of a pharmaceutically acceptable salt, in which the peptide has the ability to bind to an MHC class-I molecule and, when bound to MHC, is capable of being recognized by CD8+ T cells. A composition contains a peptide consisting of the amino acid sequence ALVEQGFTV (SEQ ID NO: 5), an adjuvant, and a pharmaceutically acceptable carrier.
-
公开(公告)号：US12076368B2
公开(公告)日：2024-09-03
申请号：US16097072
申请日：2017-04-28
Applicant: Novozymes A/S
Inventor： Peter Nordkild , Soren Kjaerulff
CPC classification number: A61K38/1729 , A61K9/0053 , A61K38/04 , A61K38/26 , A61P1/16 , A61P1/18 , A61P3/00 , A61K45/06 , A61K38/04 , A61K2300/00 , A61K38/1729 , A61K2300/00 , A61K38/26 , A61K2300/00
Abstract: The present invention relates to methods for treatment or prevention of liver, biliary tract, and pancreatic disorders by administering one or more defensins. Included within the scope of the disclosure is also treatment of certain metabolic disorders.
-
公开(公告)号：US11980658B2
公开(公告)日：2024-05-14
申请号：US17374519
申请日：2021-07-13
Applicant: ARAVAX PTY LTD
Inventor： Robyn O'Hehir , Jennifer Rolland , Sara Prickett
CPC classification number: A61K39/001 , A61K38/00 , A61K38/04 , A61K38/10 , A61K39/35 , G01N33/5005 , A61K2039/57
Abstract: The present invention relates generally to molecules such as peptides, polypeptides and proteins which interact immunologically with T lymphocytes in subjects having peanut allergy, or allergy to other tree nuts, and genetic sequences encoding same. These molecules are preferably immunointeractive with T cells in subjects having an allergy to the Ara h 1 allergen. The molecules of the present invention are useful in the development of diagnostic, therapeutic and prophylactic agents for conditions characterised by an aberrant, inappropriate or otherwise unwanted immune response to Ara h 1 or derivative or homologue thereof.
-
Patent Agency Ranking
公开(公告)号：US20240000928A1
公开(公告)日：2024-01-04
申请号：US18069489
申请日：2022-12-21
Applicant: OnkosXcel Therapeutics, LLC
Inventor： Luca RASTELLI , Aparna Katoch SAPRA , Vimal MEHTA
IPC: A61K39/395 , A61K38/04 , C12N15/113 , A61K45/06 , A61K31/69 , C07K16/28
CPC classification number: A61K39/3955 , A61K38/04 , C12N15/1137 , A61K45/06 , A61K39/39541 , A61K31/69 , C07K16/2818 , A61K2039/505
Abstract: The present invention discloses a method of treating, preventing or ameliorating tumor growth by administering a therapeutic agent that selectively inhibits dipeptidyl peptidase including fibroblast activation protein and dipeptidyl peptidase 8/9 in combination with an immune checkpoint inhibitor. The method specifically discloses use of Talabostat in combination with an immune checkpoint inhibitor, its pharmaceutical composition and process of preparing such composition.
-
公开(公告)号：US11773138B2
公开(公告)日：2023-10-03
申请号：US17506523
申请日：2021-10-20
Applicant: Theradaptive, Inc.
Inventor： Luis Alvarez
CPC classification number: C07K7/08 , A61K38/04 , A61K38/16 , A61K38/1875 , A61P19/00 , C07K14/001 , C07K14/475 , C07K14/51
Abstract: Provided herein are polypeptides that include one or more β-tricalcium phosphate (βTCP)-binding sequence(s) and uses thereof.
-
公开(公告)号：US20230279460A1
公开(公告)日：2023-09-07
申请号：US18065689
申请日：2022-12-14
Applicant: Northwestern University , Cornell University
Inventor： Michael Christopher Jewett , Jessica Carol Stark , Matthew P. DeLisa , Thapakorn Jaroentomeechai
IPC: C12P21/00 , A61K38/04 , A61K38/16 , C07K14/47 , C12N9/10 , A61K39/02 , C07K7/06 , A61K39/108 , C12P21/02 , C12N1/20
CPC classification number: C12P21/005 , A61K38/04 , A61K38/16 , C07K14/47 , C12N9/10 , C12N9/1081 , A61K39/0208 , C07K7/06 , C12Y204/99019 , A61K39/0258 , C12P21/02 , C12N1/205 , C07K9/00
Abstract: Disclosed are methods, systems, components, and compositions for cell-free synthesis of glycosylated proteins. The glycosylated proteins may be utilized in vaccines, including anti-bacterial vaccines. The glycosylated proteins may include a bacterial polysaccharide conjugated to a carrier, which may be utilized to generate an immune response in an immunized host against the polysaccharide conjugated to the carrier. The glycosylated proteins may be synthesized in cell-free glycoprotein synthesis (CFGpS) systems using prokaryote cell lysates that are enriched in components for glycoprotein synthesis such as oligosaccharyltransferases (OSTs) and lipid-linked oligosaccharides (LLOs) including OSTs and LLOs associated with synthesis of bacterial O antigens.
-
公开(公告)号：US11726087B2
公开(公告)日：2023-08-15
申请号：US16872156
申请日：2020-05-11
Applicant: CITY OF HOPE
Inventor： Markus Kalkum , Karine Bagramyan , Diana Diaz-Arevalo , James I. Ito , Sanjeet Dadwal
IPC: A61K38/08 , A01N37/18 , A61K38/00 , A61P31/10 , A61K39/00 , A61K39/395 , G01N33/53 , G01N33/573 , C12Q1/37 , C07K16/40 , G01N33/569 , C07K16/14 , A61K38/16 , A61K38/10 , A61K38/06 , A61K38/04 , A61K38/07 , G01N33/543 , G01N33/577
CPC classification number: G01N33/573 , A61K38/00 , A61K38/04 , A61K38/06 , A61K38/07 , A61K38/08 , A61K38/10 , A61K38/16 , A61K39/0002 , C07K16/14 , C07K16/40 , C12Q1/37 , G01N33/54313 , G01N33/56961 , G01N33/577 , C07K2317/622 , C07K2317/92 , G01N2333/38 , G01N2333/962
Abstract: Provided herein are methods for detecting an Aspergillus protease in a sample, diagnosing a subject with aspergillosis caused by an Aspergillus infection based on the presence of an Aspergillus protease in a sample, and methods of aspergillosis treatment that incorporate these diagnostic methods. In certain embodiments, the Aspergillus protease is Asp f2, and the Aspergillus infection is caused A. fumigatus, A. flavus, A. versicolor, A. niger, or A. terreus. Also provided herein are antibodies and kits for use in these methods, including novel antibodies specific for Asp f2.
-
公开(公告)号：US11648293B2
公开(公告)日：2023-05-16
申请号：US16866600
申请日：2020-05-05
Applicant: Biokine Therapeutics Ltd. , BioLineRx Ltd.
Inventor： Amnon Peled , Yaron Pereg
IPC: A61K39/00 , C07K16/28 , A61K38/17 , A61K38/04 , A61K47/64 , A61P35/00 , A61K38/10 , A61K39/12 , A61K39/395 , C07K16/30
CPC classification number: A61K38/1761 , A61K38/04 , A61K38/10 , A61K38/395 , A61K39/12 , A61K39/3955 , A61K47/646 , A61P35/00 , C07K16/2818 , C07K16/2827 , C07K16/30 , A61K2039/55522 , C07K2317/76 , A61K38/04 , A61K2300/00
Abstract: Use of a CXCR4 antagonistic peptide and an immune-check point regulator in the treatment of cancer is provided. Accordingly there is provided a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide having an amino acid sequence as set forth in SEQ ID NO: 1 or an analog or derivative thereof; and a therapeutically effective amount of a PD1 antagonist, a PDL-1 antagonist, a CTLA-4 antagonist, a LAG-3 antagonist, a TIM-3 antagonist, a KIR antagonist, an IDO antagonist, an OX40 agonist, a CD137 agonist, a CD27 agonist, a CD40 agonist, a GITR agonist, a CD28 agonist or an ICOS agonist, thereby treating the cancer in the subject. Also provided are pharmaceutical compositions and articles of manufacture.
-
-
-
-
-
-
-
-
-
Search Results
831
records
(took 0.039 seconds)
